Navigation Links
Dendreon Reports Third Quarter 2008 Financial Results
Date:11/7/2008

nd uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.

DENDREON CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

Revenue
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
5. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
6. Dendreon Reports First Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Announces Closing of Registered Direct Offering
9. Dendreon Announces $47 Million Registered Direct Offering
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... , , , , Vincent ... Westbury, New York , , , ... Perhaps the most critical parameter for successful , PCR is ... primer can result in a PCR reaction that will not work. The primer sequence , ...
... , , , , Karen Sermon, M.D., PhD ... Hospital and Medical School of the Dutch-speaking Brussels Free , University, , ... , , , , ... Preimplantation diagnosis (PGD) is a very early form of prenatal diagnosis: , ...
... Ends , Using the Eppendorf Mastercycler gradient , ... Ulrich Genschel , Institute of General Botany, University ... , , , , ... In many research projects, cDNA isolation forms the basis for detailed , ...
Cached Biology Technology:General Notes on Primer Design in PCR* 2General Notes on Primer Design in PCR* 3General Notes on Primer Design in PCR* 4General Notes on Primer Design in PCR* 5General Notes on Primer Design in PCR* 6The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 2The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 3The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 4The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 5Optimizing the Direct Amplification of Missing cDNA 5' Ends, Using the Eppendorf Mastercycler gradient 2Optimizing the Direct Amplification of Missing cDNA 5' Ends, Using the Eppendorf Mastercycler gradient 3Optimizing the Direct Amplification of Missing cDNA 5' Ends, Using the Eppendorf Mastercycler gradient 4Optimizing the Direct Amplification of Missing cDNA 5' Ends, Using the Eppendorf Mastercycler gradient 5
(Date:4/16/2014)... Florida State University researchers have identified a new syndrome ... density and muscle mass with obesity. , "It used ... the better your bones would be because the bones ... Stiebeling Professor of Nutrition at Florida State. "But, that,s ... outlined in the May issue of Ageing Research ...
(Date:4/16/2014)... - Geoscientists from the north-central U.S. and beyond will ... discuss new science, expand on existing science, and explore ... with a special emphasis on applied geology, paleontology, and ... p.m. on Thursday by Dr. Kirk Johnson, Sant Director ... , The meeting is hosted by the University of ...
(Date:4/16/2014)... the world? Surprisingly, bacteria also face this problem. ... now shown how these organisms should decide how ... Bacillus subtilis is quite adaptable. It ... by means of flagella. Alternatively, it can stick ... most effectively in this stationary state, while motile ...
Breaking Biology News(10 mins):Researchers: Obesity can amplify bone and muscle loss 2Walking with mammoths and exploring mid-continental geology 2Walking with mammoths and exploring mid-continental geology 3Walking with mammoths and exploring mid-continental geology 4Theoretical biophysics: Adventurous bacteria 2
... about 6 percent of total births worldwide -- are born ... origin, according to a new report from the March of ... serious birth defects of post-conception origin due to maternal exposure ... the March of Dimes Global Report on Birth Defects: ...
... discovered that some type of protective system goes into ... is deficient. This discovery indicates a hidden safety net ... the immune system such as AIDS. The Mayo Clinic-led ... and is reported in the early online edition of ...
... uncovered part of the genetic mechanism that causes new arteries ... led by SFVAMC vascular surgeon Rajabrata Sarkar, MD, PhD, has ... the growth of new arteries when the femoral (leg) artery ... for the first time, the specific DNA sequences of the ...
Cached Biology News:Birth defects: 8 million annually worldwide 2Birth defects: 8 million annually worldwide 3Birth defects: 8 million annually worldwide 4Birth defects: 8 million annually worldwide 5Infant transplant patients resist infections that kill adult AIDS patients 2Infant transplant patients resist infections that kill adult AIDS patients 3Genetic key to growth of new arteries is identified 2Genetic key to growth of new arteries is identified 3
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Recombinant Equine IL-6...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
... Express Cloning Checker Kits provide two ... after transformation without time-consuming plasmid preparation. By ... I, all you need to do is ... bacteria directly from the transformation plates into ...
Biology Products: